Dividend Win Wednesday: Insiders Exit Energy at Highs While Pharma Wins Approvals

This Week's Setup

Fear sits at 35 on the index, a level that historically marks the edge of sentiment capitulation without the volatility spike that forces institutional rebalancing.

The S&P 500 CAPE holds at 38.9, a valuation that has capped equity multiples in four of the last six cycles, while the dividend screen is pulling eight names with FCF yields between 4.4% and 11.2%, drawdowns no wider than 17%, and insider activity that cuts both directions.

Energy names dominate the top ranks as a $7 billion Venezuela oil deal reshapes supply expectations and pharma names post trial wins while insiders exit at all-time highs.

Quick Scan

The 8 Names

1. EOG Resources, Inc. (EOG)

Dividend yield: 2.8% | Payout ratio: 44% | 52w drawdown: 4%

The earnings yield sits at 6.9% while the company carries a net debt-to-EBITDA ratio of 0.35, one of the cleanest balance sheets in the exploration and production sector. Interest coverage of 28× leaves wide operational margin even if commodity prices compress in the next 12 months.

Revenue contracted 3.4% year-over-year while the normalized P/E of 14.5 prices in production stability, not the growth that typically justifies a 7% yield spread to Treasuries.

Insiders sold across the board in the last 30 days: Ezra Yacob and Christopher Gaut both exited positions in late August, with a net reduction of 14,343 shares over six months and zero offsetting buys. Short interest at 3.4% of float is unremarkable.

Gross margin of 63% depends on sustained commodity pricing while the Venezuela deal announced this week adds 200,000 barrels per day to global supply, a margin headwind if WTI tests support below $70.

2. ConocoPhillips (COP)

Dividend yield: 2.5% | Payout ratio: 51% | 52w drawdown: 1%

The stock trades 1% below its 52-week high with an FCF yield of 4.4%, returning cash at a rate that covers the dividend twice over while maintaining an EV-to-EBITDA multiple of 6.8×, well below the sector median.

Three insiders filed Form 4 transactions between August 24 and September 2: Jaramillo Mejia Ricardo, Silvina Vatnick, and Sylvia Escovar Gomez. The filings show activity but no dollar amounts or directional bias in the public record, leaving the signal ambiguous.

The Venezuela deal announced this week commits Chevron to a $7 billion investment and raises the production baseline for competing Permian operators, compressing the spread advantage COP has held since mid-2025. Analysts hold a $142.77 target, 6% above current price, pricing in stability rather than expansion.

3. Novartis AG (NVS)

Dividend yield: 2.9% | Payout ratio: 65% | 52w drawdown: 3%

⬡ Remibrutinib trial results for multiple sclerosis moved the stock 3% higher on the week, validating the BTK inhibitor mechanism that has been contested in neurology since 2024. The drug targets a $25 billion MS market where Roche's ocrelizumab still holds 40% share.

Revenue growth of 9.6% year-over-year supports a gross margin of 75.8%, the widest in the pharma peer set, while ROIC of 16% exceeds the cost of capital by 900 basis points. The payout ratio of 65% leaves room for dividend growth even as the company carries net debt-to-EBITDA of 1.75.

Analysts set a $153.87 target, 4.5% below the current price of $161, signaling the valuation has run past near-term catalysts. The next earnings call on October 27 will clarify whether remibrutinib justifies the premium or if the multiple needs to contract.

4. Biogen Inc. ([BIIB])

Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: 2%

FCF yield of 6.2% is the third-highest in the pharma sector while the company pays no dividend, routing cash into immunology bets and balance sheet repair. Net debt-to-EBITDA of 0.64 is half the industry average, giving management flexibility to acquire assets or return capital without covenant pressure.

Lloyd Minor bought shares on August 5, the only insider transaction in the last 30 days. The purchase adds to a six-month pattern showing 10 insider buys and 3 net shares added, a modest directional signal in a market where pharma insiders have been net sellers since April.

Zorevunersen trial data for Dravet syndrome will be presented at the European Epilepsy Congress this month, but the drug is a partnership with Stoke Therapeutics and any upside splits between the two companies. October 29 earnings are expected to show $2.04 EPS on $2.6 billion revenue, flat year-over-year, leaving little room for positive surprises.

5. Newmont Corporation (NEM)

Dividend yield: 0.8% | Payout ratio: 16% | 52w drawdown: 7%

The company carries negative net debt, one of two miners in the S&P 500 with a net cash position, while revenue grew 21% year-over-year and ROIC expanded to 29.8%. Interest coverage of 50× is academic when the company has no meaningful debt to service.

The payout ratio of 16% is the lowest in the screen, reflecting management's choice to prioritize reinvestment over shareholder distributions even as FCF yield sits at 5.5%. Analysts price in 14% upside to a $142.82 target, but the dividend itself offers no income catalyst.

Three insiders sold in early August: Peter Toth, Brian Tabolt, and Natascha Viljoen exited a combined 18,394 shares over six months with zero offsetting buys. The selling pattern suggests executives are locking in gains near all-time highs rather than expressing bearish conviction.